Randomized trial shows pramipexole reduced depressive symptoms in treatment-resistant depression patients, suggesting potential benefits despite adverse events.
Augmenting antidepressant treatment with the dopamine D2/D3 receptor agonist pramipexole led to improvement in depressive symptoms relative to placebo at 12 weeks in patients with treatment‐resistant depression, a randomized trial has found. Treatment discontinuation due to adverse events was more prevalent in the pramipexole group, investigators reported. Study results were published online June 29, 2025, in Lancet Psychiatry .
No takes yet. Share an insight, caveat, or question.
A 2025 study studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: